Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

The Lancet

Volumn 391, Issue 10120, 2018, Pages 552-562

  Gaudinski, Martin R ^a   Houser, Katherine V ^a   Morabito, Kaitlyn M ^a   Hu, Zonghui ^a   Yamshchikov, Galina ^a   Rothwell, Ro Shauna ^a   Berkowitz, Nina ^a   Mendoza, Floreliz ^a   Saunders, Jamie G ^a   Novik, Laura ^a   Hendel, Cynthia S ^a   Holman, LaSonji A ^a   Gordon, Ingelise J ^a   Cox, Josephine H ^a   Edupuganti, Srilatha ^b   McArthur, Monica A ^c   Rouphael, Nadine G ^b   Lyke, Kirsten E ^c   Cummings, Ginny E ^c   Sitar, Sandra ^a   Bailer, Robert T ^a   Foreman, Bryant M ^a   Burgomaster, Katherine ^a   Pelc, Rebecca S ^a   Gordon, David N ^a   DeMaso, Christina R ^a   Dowd, Kimberly A ^a   Laurencot, Carolyn ^a   Schwartz, Richard M ^a   Mascola, John R ^a   Graham, Barney S ^a   Pierson, Theodore C ^a   Ledgerwood, Julie E ^a   Chen, Grace L ^a   Plummer, Sarah ^d   Costner, Pamela ^d   Zephir, Kathryn ^d   Casazza, Joseph ^d   Ola, Abidemi ^d   Victorino, Milalynn ^d   Levinson, Carol ^d   Whalen, William ^d   Wang, Xiaolin ^d   Cunningham, Jennifer ^d,d   Vasilenko, Olga ^d   Burgos Florez, Maria ^d   Hickman, Somia ^d   Pittman, Iris ^d   Le, Lam ^d   Larkin, Brenda ^d   Andrews, Charla ^d   Apte, Preeti ^d   Hicks, Renunda ^d   Trelles Cartagena, Cora ^d   Williams, Pernell ^d   Boyd, Catina R ^d   Conan Cibotti, Michelle ^d   Stein, Judy ^d   Kaltovich, Florence ^d   DeCederfelt, Hope ^d   McAdams, Stacey ^d   Renehan, Phyllis ^d   Chen, Wilbur ^d   Greenberg, Nancy ^d   Wymer, Nancy ^d   Wadsworth, Linda ^d   Billington, Melissa ^d   Robinson, Toni ^d   Boyce, Colleen ^d   Pa'ahana Brown, Faith ^d   Chrisley, Lisa ^d   Kwon, Alyson ^d   Patel, Prashant ^d   Kominou, Panagoita ^d   Dorsey, Brenda ^d   Eddington, Staci ^d   Telscher, Shinyi ^d   Lee, Myoughee ^d   Mosely, Regina ^d   Ross, April ^d   Ford, Geoffrey ^d   Domjahn, Briyana ^d   Xu, Jianguo ^d   Beck, Allison ^d   Fineman, Rebecca ^d   Heeke, Shiela ^d   Winter, Jean ^d   Nagar, Shashi ^d   Kelley, Colleen ^d   Mulligan, Mark ^d   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; PLASMID VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE; VRC 5283; VRC 5288; CYTOKINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONGENITAL INFECTION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS VIRUS; KIDNEY CELL; MALAISE; MALE; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRATIS DEVICE; TREATMENT WITHDRAWAL; VACCINE IMMUNOGENICITY; ZIKA FEVER; ZIKA VIRUS; BIOSYNTHESIS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; T LYMPHOCYTE; YOUNG ADULT;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, DNA; VIRAL VACCINES; YOUNG ADULT; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85037039416     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)33105-7     Document Type: Article

References (32)

1. Fauci, AS, Morens, DM, Zika virus in the Americas—yet another arbovirus threat. N Engl J Med 374 (2016), 601–604.
2. Dick, GW, Kitchen, SF, Haddow, AJ, Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46 (1952), 509–520.
3. Duffy, MR, Chen, T-H, Hancock, WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360 (2009), 2536–2543.
4. Derraik, JG, Slaney, D, Notes on Zika virus—an emerging pathogen now present in the South Pacific. Aust NZ J Public Health 39 (2015), 5–7.
5. Campos, GS, Bandeira, AC, Sardi, SI, Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 21 (2015), 1885–1886.
6. D'Ortenzio, E, Matheron, S, Yazdanpanah, Y, et al. Evidence of sexual transmission of Zika virus. N Engl J Med 374 (2016), 2195–2198.
7. Motta, IJ, Spencer, BR, Cordeiro da Silva, SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 375 (2016), 1101–1103.
8. Vasquez, AM, Sapiano, MR, Basavaraju, SV, Kuehnert, MJ, Rivera-Garcia, B, Survey of blood collection centers and implementation of guidance for prevention of transfusion-transmitted Zika virus infection—Puerto Rico, 2016. MMWR Morb Mortal Wkly Rep 65 (2016), 375–378.
9. Ikejezie, J, Shapiro, CN, Kim, J, et al. Zika virus transmission—region of the Americas, May 15, 2015–December 15, 2016. MMWR Morb Mortal Wkly Rep 66 (2017), 329–334.
10. Heymann, DL, Hodgson, A, Sall, AA, et al. Zika virus and microcephaly: why is this situation a PHEIC?. Lancet 387 (2016), 719–721.
11. Krauer, F, Riesen, M, Reveiz, L, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review. PLoS Med, 14, 2017, e1002203.
12. de Oliveira, WK, de Franca, GVA, Carmo, EH, Duncan, BB, de Souza Kuchenbecker, R, Schmidt, MI, Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet 390 (2017), 861–870.
13. Martin, JE, Louder, MK, Holman, LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 26 (2008), 6338–6343.
14. Martin, JE, Sullivan, NJ, Enama, ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13 (2006), 1267–1277.
15. Beckett, CG, Tjaden, J, Burgess, T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 29 (2011), 960–968.
16. Martin, JE, Pierson, TC, Hubka, S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196 (2007), 1732–1740.
17. Ledgerwood, JE, Wei, CJ, Hu, Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11 (2011), 916–924.
18. Sheets, RL, Stein, J, Manetz, TS, et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 91 (2006), 620–630.
19. Graham, BS, Koup, RA, Roederer, M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 (2006), 1650–1660.
20. Allison, SL, Stadler, K, Mandl, CW, Kunz, C, Heinz, FX, Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 69 (1995), 5816–5820.
21. Davis, BS, Chang, GJ, Cropp, B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75 (2001), 4040–4047.
22. Dowd, KA, Ko, SY, Morabito, KM, et al. Rapid development of a DNA vaccine for Zika virus. Science 354 (2016), 237–240.
23. Davis, CW, Nguyen, HY, Hanna, SL, Sánchez, MD, Doms, RW, Pierson, TC, West Nile virus discrimintates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 80 (2006), 1290–1301.
24. Sarwar, UN, Costner, P, Enama, ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 211 (2015), 549–557.
25. Pierson, TC, Diamond, MS, Vaccine development as a means to control dengue virus pathogenesis: do we know enough?. Ann Rev Virol 1 (2014), 375–398.
26. Larocca, RA, Abbink, P, Peron, JP, et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
27. Bukowski, JF, Kurane, I, Lai, CJ, Bray, M, Falgout, B, Ennis, FA, Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol 63 (1989), 5086–5091.
28. Mongkolsapaya, J, Dejnirattisai, W, Xu, XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9 (2003), 921–927.
29. Screaton, G, Mongkolsapaya, J, Yacoub, S, Roberts, C, New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 15 (2015), 745–759.
30. Liang, H, Lee, M, Jin, X, Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol 13 (2016), 36–46.
31. Graham, BS, Enama, ME, Nason, MC, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One, 8, 2013, e59340.
32. Tebas, P, Roberts, CC, Muthumani, K, et al. Safety and immunogencity of an anti-Zika virus DNA vaccine—preliminary report. N Engl J Med, 2017 published online Oct 4. DOI:10.1056/NEJMoa1708120.